Feng-mei Zhou

State Key Laboratory Of Metabolic Dysregulation & Prevention And Treatment Of Esophageal Cancer
Zhengzhou, 450002, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Novel role of MKRN2 in regulating tumor growth through host microenvironment and macrophage M1 to M2 switch.

Novel role of MKRN2 in regulating tumor growth through host microenvironment and macrophage M1 to M2 switch.

Journal: Cancer letters

Published: July 22, 2025

Hexavalent chromium induced metabolic reprogramming, carcinogenesis and tumor progression through PDK1 upregulation.

Hexavalent chromium induced metabolic reprogramming, carcinogenesis and tumor progression through PDK1 upregulation.

Journal: Ecotoxicology and environmental safety

Published: July 16, 2024

CIB2 mediates acquired gefitinib resistance by inducing ZEB1 expression and epithelial-mesenchymal transition.

CIB2 mediates acquired gefitinib resistance by inducing ZEB1 expression and epithelial-mesenchymal transition.

Journal: Aging

Published: February 20, 2024

HK2 and LDHA upregulation mediate hexavalent chromium-induced carcinogenesis, cancer development and prognosis through miR-218 inhibition.

HK2 and LDHA upregulation mediate hexavalent chromium-induced carcinogenesis, cancer development and prognosis through miR-218 inhibition.

Journal: Ecotoxicology and environmental safety

Published: November 14, 2023

MKRN2 knockout causes male infertility through decreasing STAT1, SIX4, and TNC expression.

MKRN2 knockout causes male infertility through decreasing STAT1, SIX4, and TNC expression.

Journal: Frontiers in endocrinology

Published: January 05, 2023

Elevated NOX4 promotes tumorigenesis and acquired EGFR-TKIs resistance via enhancing IL-8/PD-L1 signaling in NSCLC.

Elevated NOX4 promotes tumorigenesis and acquired EGFR-TKIs resistance via enhancing IL-8/PD-L1 signaling in NSCLC.

Journal: Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy

Published: October 04, 2022

Corrigendum: Regulation of microrna-497-targeting AKT2 influences tumor growth and chemoresistance to cisplatin in lung cancer.

Corrigendum: Regulation of microrna-497-targeting AKT2 influences tumor growth and chemoresistance to cisplatin in lung cancer.

Journal: Frontiers in cell and developmental biology

Published: July 31, 2022

Discovery of a New CDK4/6 and PI3K/AKT Multiple Kinase Inhibitor Aminoquinol for the Treatment of Hepatocellular Carcinoma.

Discovery of a New CDK4/6 and PI3K/AKT Multiple Kinase Inhibitor Aminoquinol for the Treatment of Hepatocellular Carcinoma.

Journal: Frontiers in pharmacology

Published: April 07, 2021

Discovery of vanoxerine dihydrochloride as a CDK2/4/6 triple-inhibitor for the treatment of human hepatocellular carcinoma.

Discovery of vanoxerine dihydrochloride as a CDK2/4/6 triple-inhibitor for the treatment of human hepatocellular carcinoma.

Journal: Molecular medicine (Cambridge, Mass.)

Published: May 14, 2020

Regulation of MicroRNA-497-Targeting AKT2 Influences Tumor Growth and Chemoresistance to Cisplatin in Lung Cancer.

Regulation of MicroRNA-497-Targeting AKT2 Influences Tumor Growth and Chemoresistance to Cisplatin in Lung Cancer.

Journal: Frontiers in cell and developmental biology

Published: May 05, 2020

Apigenin Inhibits IL-6 Transcription and Suppresses Esophageal Carcinogenesis.

Apigenin Inhibits IL-6 Transcription and Suppresses Esophageal Carcinogenesis.

Journal: Frontiers in pharmacology

Published: May 24, 2019

Suppression of miR-143 contributes to overexpression of IL-6, HIF-1α and NF-κB p65 in Cr(VI)-induced human exposure and tumor growth.

Suppression of miR-143 contributes to overexpression of IL-6, HIF-1α and NF-κB p65 in Cr(VI)-induced human exposure and tumor growth.

Journal: Toxicology and applied pharmacology

Published: March 11, 2019

Showing 1-12 of 14

Last Updated: 09/26/2026